Back to news

Asimov and Emergent Biosolutions Announce Cell Line Development Partnership to Advance Novel Antibodies Against Ebola

Globe Newswire•16/11/2026•16:01 ET
0

Key Highlights

  • ➤Emergent and Asimov launch two cell line development campaigns for Ebola antibodies
  • ➤Partnership spans vector design, synthesis, and high-titer research cell bank shipment
  • ➤Emergent will use Asimov’s CHO Edge System to develop high-titer cell lines
  • ➤Asimov has raised over $200 million from institutional investors

Expert Statements

Alec Nielsen, Co-founder and CEO of Asimov

“We are proud to partner with Emergent as they develop medical countermeasures to strengthen our ability to combat biological threats.”

Alec Nielsen, Co-founder and CEO of Asimov

“Emergent has a long history of developing essential medicines, and we look forward to working with their team on this important work.”

Joe Papa, President and CEO of Emergent

“Ebola remains one of the most serious health threats, demanding continued innovation and investment in next-generation medical countermeasures,”

Joe Papa, President and CEO of Emergent

“By utilizing Asimov’s AI-native advanced cell line development capabilities in combination with Emergent’s deep expertise in biodefense, we aim to accelerate the development of novel antibody candidates that have the potential to strengthen preparedness and help protect and save lives.”

BOSTON and GAITHERSBURG, Md., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, and Emergent Biosolutions (NYSE: EBS), a leading global public health company, today announced a cell line development partnership. The partnership covers two full cell line development campaigns, from vector design and synthesis through the production and shipment of a high-titer research cell bank, for two monoclonal antibodies targeting Ebola.

“We are proud to partner with Emergent as they develop medical countermeasures to strengthen our ability to combat biological threats,” said Alec Nielsen, co-founder and CEO of Asimov. “Emergent has a long history of developing essential medicines, and we look forward to working with their team on this important work.”

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in